Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach.

Other PARP inhibitors have validated the mechanism of action in cancers of the ovary, breast, prostate and pancreas. IDX-1197 has several key advantages over those commercially available PARP ...

PARP inhibitors work by working on a DNA repair mechanism that is present in certain fast-growing tumours – blocking the action of the PARP protein that is part of the mechanism causes cancer ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival ...

I would like to further investigate the underlying mechanism of this combination drug and optimize the dosage. In our study, we used lower dosages of both AZA and BMN673 at a fixed ratio of one to one ...